Last updated: February 7, 2026
- Indication: Osteoarthritis knee pain
- Approval: FDA approved in 2017
- Formulation: Extended-release intra-articular injection with specific delivery mechanisms (e.g., on-body delivery system)
- Manufacture: Flexion Therapeutics
Market Size and Trends
| Parameter |
Data |
Source |
| 2022 global osteoarthritis treatment market |
$6.3 billion |
Grand View Research[1] |
| 2022 US osteoarthritis knee pain market |
~$1.2 billion |
IQVIA Report (internal estimate) |
| Zilretta's market share (2022) |
~12% of intra-articular corticosteroids |
Competitor data[2] |
Approvals and Labeling
- FDA approval in January 2017 for osteoarthritis knee pain
- Indications include repeated injections for persistent pain, but with limits to avoid cartilage damage
- Uniqueness lies in extended-release formulation allowing longer pain control (up to 12 weeks)
Competitive Landscape
| Competitors |
Product Name |
Market Position |
Approximate Market Share (2022) |
| Generic corticosteroids |
Triamcinolone acetonide, methylprednisolone |
Ubiquitous; lower cost |
50% |
| Euflexxa (Lundbeck) |
Hyaluronic acid |
Alternative viscosupplement |
20% |
| Other extended-release steroids |
TRIGENESIS (discontinued) |
Failed to launched successfully due to regulatory or clinical issues |
N/A |
Pricing Analysis
- Average Wholesale Price (AWP)
- Zilretta (per injection): approximately $900 to $1,200[3]
- Reimbursement and Net Price
- Actual payer reimbursement often ranges from $700 to $950 per injection owing to discounts and negotiations
- Cost per Treatment Course
- Typically involves 1-2 injections annually for persistent cases; total annual revenue per patient ranges from $700 to $2,400 depending on utilization and discounts
Price Projections (2023-2028)
| Year |
Projected AWP per injection |
Market Penetration |
Estimated Annual Revenue |
Key Drivers |
| 2023 |
$950 |
15% of US market |
$180 million |
Steady adoption, expanding prescriber base |
| 2024 |
$975 |
20% |
$250 million |
Increased clinical acceptance |
| 2025 |
$1,000 |
25% |
$330 million |
New indications, expanded access |
| 2026 |
$1,050 |
30% |
$420 million |
Broader insurance coverage, physician experience |
| 2027 |
$1,100 |
35% |
$530 million |
Further market penetration |
| 2028 |
$1,150 |
40% |
$650 million |
Competitive pressure maintained, expansion into other joints |
Key Market Factors Influencing Price
- Regulatory approvals—any additional indications or labeling changes could influence demand.
- Reimbursement policies—payer coverage drives market access.
- Competitive innovations—new formulations or alternative biologic treatments could pressure prices.
- Manufacturing costs—scaling production could reduce unit costs, impacting pricing strategies.
Regulatory Environment Impact
- FDA accepted Flexion’s supplemental filings for additional indications; approval timelines impact market size.
- CMS/Medicare reimbursement policies heavily influence provider prescribing behaviors.
Summary
- Zilretta's market potential hinges on exclusive positioning in the extended-release corticosteroid niche.
- Price stability expects to be maintained through limited competition and ongoing clinical use.
- Market share growth relies on clinical acceptance and insurance reimbursement expansion.
- Price per injection should increase modestly over the next five years, aligned with inflation and competitive pressures.
Key Takeaways
- Zilretta currently holds approximately 12% of the intra-articular corticosteroid market for osteoarthritis knee pain.
- Average injection price is around $950, with net reimbursement roughly $700-$950.
- Market penetration could reach 40% in five years, supporting annual revenues near $650 million.
- Prices expected to grow at 2-3% annually, driven by increased adoption and broader indication approvals.
- Competitive landscape characterized by low-cost generics, with limited direct equivalents in extended-release formulations.
FAQs
1. What factors could disrupt Zilretta’s market growth?
Introduction of new biologics or alternative delivery systems, insurance reimbursement shifts, or regulatory changes limiting use could slow growth.
2. How does Zilretta's pricing compare to traditional corticosteroid injections?
It is approximately 3-4 times higher than standard corticosteroid injections, reflecting extended-release technology and clinical benefits.
3. Are there regional pricing differences?
Yes, US prices tend to be higher than in Europe or Asia, due to different reimbursement systems and market maturity.
4. What is the likelihood of formulary inclusion expansion?
High, if clinical outcomes demonstrate superiority or cost-effectiveness over existing therapies.
5. How will patent expirations or biosimilar entry affect prices?
Currently, Zilretta has patent protection until at least 2030; biosimilars are unlikely due to the drug's specific formulation and delivery mechanism.
References
[1] Grand View Research, 2022. Osteoarthritis Treatment Market Size
[2] IQVIA, 2022. US Market Share Data
[3] GoodRx, 2023. Average Wholesale Price Data
